 Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific updates. Arvinas Inc NASDAQ: ARVN: The smid-cap biopharma announced clinical program updates for its protein degraders ARV-471 and ARV-110. 